DEA Schedule III Registration Opens to Cannabis Cultivators, Labs and Manufacturers

The DEA Schedule III registration window — open since April 29, 2026, for state-licensed medical cannabis dispensaries — is about to widen dramatically. In a notice published this month, the Drug Enforcement Administration confirmed that purpose-built application forms for cannabis cultivators, manufacturers, distributors and analytical testing labs will be posted on the agency's Diversion site in the coming weeks, with an expedited review window closing in late June 2026.

For roughly 8,000 non-dispensary cannabis operators across the United States, the stakes are enormous. Schedule III registration is what turns the Justice Department's April 24 final order — moving FDA-approved and qualifying state-licensed medical cannabis from Schedule I to Schedule III — into a workable framework for cultivation, manufacturing, and lab testing.

What Changed Last Week

The DEA's earlier April rollout focused exclusively on dispensaries, using existing Form 224 architecture and the new "Medical Marijuana Dispensary" classification. Cultivators, manufacturers, distributors, and labs were forced into a holding pattern: they could file Form 225 with one of three medical marijuana drug codes — 7362 (THC), 7353 (CBD), or 7386 (full-spectrum medical cannabis) — but the agency made clear that purpose-built forms were forthcoming.

According to confirmation from DEA Diversion, that wait is nearly over. Four new application types are coming:

• Medical Marijuana Manufacturer (Form 225 variant)
• Medical Marijuana Bulk Manufacturer (grower/cultivator designation)
• Medical Marijuana Analytical Lab
• Medical Marijuana Distributor

Each form will let DEA flag the registrant specifically for Schedule III medical cannabis activity — separate from existing Schedule II or Schedule III manufacturing registrations that pharmaceutical companies already hold. The agency expects to post the updated applications on dea.gov/diversion before the end of the expedited 60-day registration window.

The Late-June Deadline That Actually Matters

For operators chasing federal legitimacy, calendar math is unforgiving. The Federal Register published the DOJ's final rescheduling order on April 28, 2026. The 60-day window that triggers expedited review and interim operating protections closes on June 26, 2026. Because June 27 is a Saturday, filings submitted on the next federal business day will be treated as timely — but no later than June 29, 2026.

What does "expedited review" actually unlock? Three things, according to attorneys at Gibson Dunn and Foley & Lardner who have advised dozens of state-licensed operators:

1. Continuity of operations — applicants who file within the 60-day window may continue operating under their state license while DEA processes the application. Operators who file after that lose presumed continuity and must wait for an affirmative DEA approval before any cross-state activity.
2. Priority queue placement — early filings move ahead of the standard backlog, which DEA acknowledges runs months to years for new Schedule III applicants.
3. Federal tax treatment — 280E relief depends on operating under a registered Schedule III framework. Filing late doesn't disqualify operators, but it does delay the tax break that has reshaped Q1 earnings calls from Curaleaf to Cresco.

The expedited window does not apply to recreational-only operators. Adult-use licensees that do not also hold medical-use designation cannot register at all under the current rule. That gap is what California's emergency dual-license rulemaking — published this week — is designed to address.

Why Cultivators Got Stuck

Cultivators have faced the most complex compliance lift. Unlike dispensaries, which mostly need a building inspection, security plan, and recordkeeping system, large cannabis grows must demonstrate compliance with DEA's tightened Schedule III bulk manufacturing standards: vaulted storage, chain-of-custody logs, separation of plant material by drug code, and detailed cultivation records tied to harvest batches.

Multistate operators have been quietly investing in compliance teams for months. Cresco Labs disclosed during its Q1 2026 earnings call that it had completed four facility-level DEA registrations across its medical cannabis network, including cultivation sites in Pennsylvania, Ohio, and Massachusetts. Trulieve, Verano and Green Thumb Industries have signaled similar progress, though only Cresco has publicly counted facilities.

Analytical labs face a different problem: drug code coverage. The current 7362/7353/7386 trio covers most active-ingredient testing, but labs that run cannabis-specific contaminant panels — heavy metals, mycotoxins, residual solvents — must demonstrate that their analytical work falls within the scope of a Schedule III registration rather than triggering a separate Schedule I research registration. The forthcoming "Medical Marijuana Analytical Lab" designation is supposed to close that gap.

What Operators Should Do This Week

For non-dispensary cannabis businesses, the practical to-do list is short but unforgiving:

• Inventory current DEA exposure. Identify every facility that handles plant material — cultivation, manufacturing, distribution, testing. Each will need a separate registration tied to a specific facility address.
• Pull state license documentation. DEA requires proof of a current, in-good-standing state license for the medical-use designation. In states like California, that means securing the new secondary medical license before submitting.
• Confirm Suspicious Order Monitoring infrastructure. Schedule III registrants are subject to SOM reporting requirements, which most cannabis operators have never implemented.
• File Form 225 now, then amend. Multiple practitioners advise filing Form 225 with the appropriate drug code immediately and amending to the new forms when they are posted, rather than waiting and missing the June 26 cutoff.

The DEA has not committed to a hard publication date for the new forms. Operators who hold off risk arriving inside a 24-to-72-hour scramble that registration consultants — CannDelta, Cannashield, and others — say is already overwhelming their queues.

What This Means for the Broader Industry

The rescheduling story has so far been told primarily through the lens of dispensaries and the consumer-facing tax relief that 280E removal brings. The opening of Schedule III registration to cultivators, manufacturers, distributors and labs marks the start of a deeper change: vertical integration of compliance, where every link in the medical cannabis supply chain holds a federal registration alongside its state license.

That has consequences beyond tax. It enables interstate medical cannabis movement — long blocked by federal Schedule I status — once both states involved have a federally registered medical framework. It allows clinical research that pulls product directly from state-regulated cultivation rather than the long-criticized University of Mississippi research-grade supply. And it creates, for the first time, a federally documented chain of custody for medical cannabis that pharmaceutical wholesalers and insurance plans can trust.

The DEA's broader rescheduling hearing — scheduled to begin June 29, 2026, and conclude no later than July 15 — will decide whether all marijuana, including adult-use, eventually joins Schedule III. Until that decision lands, this 60-day cultivator-and-lab window is the immediate test of whether the federal medical cannabis framework can scale.

Key Takeaways

• DEA will post Schedule III registration forms for cannabis cultivators, manufacturers, distributors and analytical labs in the coming weeks.
• Filings made on or before June 26, 2026 (or the next business day, June 29) qualify for expedited review and interim operating protections.
• Cresco Labs has already registered four medical cannabis facilities; other multistate operators are close behind.
• Recreational-only licensees remain ineligible — California's new dual-license rule is designed to give operators a pathway in.
• The broader DEA rescheduling hearing begins June 29 and will determine whether non-medical cannabis follows the same path.

Explore cannabis news, find dispensaries, and join the community at Budpedia.